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Objective: Avoiding withdrawal symptoms following antipsychotic discontinuation is an
important factor when planning a safe therapy. We performed a systematic review and
meta-analysis concerning occurrence of withdrawal symptoms after discontinuation
of antipsychotics.
Data Sources: We searched the databases CENTRAL, Pubmed, and EMBASE with no
restriction to the beginning of the searched time period and until October 1, 2019
(PROSPERO registration no. CRD42019119148).
Study Selection: Of the 18,043 screened studies, controlled and cohort trials that
assessed withdrawal symptoms after discontinuation of oral antipsychotics were included
in the random-effects model. Studies that did not implement placebo substitution were
excluded from analyses. The primary outcome was the proportion of individuals with
withdrawal symptoms after antipsychotic discontinuation. We compared a control group
with continued antipsychotic treatment in the assessment of odds ratio and number
needed to harm (NNH).
Data Extraction: We followed guidelines by the Cochrane Collaboration, PRISMA,
and MOOSE.
Results: Five studies with a total of 261 individuals were included. The primary outcome,
proportion of individuals with withdrawal symptoms after antipsychotic discontinuation,
was 0.53 (95% CI, 0.37–0.70; I2 = 82.98%, P < 0.01). An odds ratio of 7.97 (95% CI,
2.39–26.58; I2 = 82.7%, P = 0.003) and NNH of 3 was calculated for the occurrence of
withdrawal symptoms after antipsychotic discontinuation.
Conclusion:Withdrawal symptoms appear to occur frequently after abrupt discontinuation
of an oral antipsychotic. The lack of randomized controlled trials with low risk of bias on
antipsychotic withdrawal symptoms highlights the need for further research.
Keywords: antipsychotics, withdrawal symptoms, discontinuation symptoms, systematic review, meta-analysisg September 2020 | Volume 11 | Article 5699121
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Antipsychotics are primarily used in the treatment of psychotic
disorders, which are in most cases associated with delusions and
hallucinations (1). One of the most important indications are
positive symptoms in schizophrenia (1). Furthermore,
antipsychotics are used in a variety of other mental illnesses,
such as bipolar affective disorder, psychotic depression, and
agitation in neurodegenerative disorders.
Antipsychotic drugs are a heterogeneous group of compounds
with a high variability of receptor affinities (2). The clinical effects of
the individual compounds are diverse, since receptor affinity is an
important factor for the efficacy, but especially for the side effect
profile (3) and possibly for the withdrawal symptoms (4). The
definition of a specific antipsychotic withdrawal syndrome is being
debated (4, 5) and withdrawal symptoms may be associated with
adverse events not previously complained of by the patient (6)
such as cholinergic, dopaminergic, serotonergic, histaminergic,
and adrenergic symptoms (2). Providing the appropriate
discontinuation strategy for antipsychotic compounds is a complex
task and depends on the side effect profile, pharmacodynamics and
-kinetics of the compound, behavioral mechanisms as well as
comorbidities and vulnerabilities of the patient (4, 7). However,
clinical data is partly based on trials from prior to the 1980s (8).
Recent research (4, 5) and schizophrenia guidelines (9) highlight the
need for research in thisfield.To reduce the risk todevelop long-term
side effects, such as metabolic syndrome or tardive dyskinesia,
different guidelines (e.g., by the National Institute for Health and
Clinical Excellence in the United Kingdom (10)) recommend dose
reductionor in certain cases antipsychoticwithdrawal especially after
the first psychotic episode.
Occurrence of withdrawal symptoms is not limited to
psychopharmacological drugs (11) such as antipsychotics or
antidepressants (12) or psychiatric patients (13) but have also
been reported in other compounds such as beta-adrenergic
receptor antagonists (14) or alpha-2 adrenergic agents (15) (used
in the treatment of arterial hypertension) and can be expected
following the abrupt discontinuation of many drugs (14).
Individuals with antipsychotic withdrawal symptoms typically do
not fulfil the addiction criteria as defined by the International
Classification of Diseases (ICD-10 (11, 16). The main mechanism
in the development of withdrawal symptoms is considered to be
neuroadaptation to the predominantly antagonist effects of
antipsychotics on different receptor systems and reactive
homeostasis that is lost when dosing intake is stopped but the
exact process remains to be elucidated (4, 5).
The primary research question (PICOS framework) of this
systematic review and meta-analysis was: In patients treated with
antipsychotics, what is the effect of antipsychotic discontinuation
compared to no antipsychotic discontinuation or in uncontrolled
designs on the occurrence of withdrawal symptoms?
METHODS
The protocol for this systematic review and meta-analysis has a
priori been published (PROSPERO registration no.
CRD42019119148). We followed guidelines by the Cochrane
Collaboration for conducting systematic reviews (17) and theFrontiers in Psychiatry | www.frontiersin.org 2Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) (18) and Meta-analysis of Observational
Studies in Epidemiology (MOOSE) for extracting and assessing
data (19).
Search Strategy
The database search included CENTRAL, Pubmed, and
EMBASE with no restriction to the beginning of the searched
time period and until October 1, 2019. Title, abstracts, and key
words were searched with terms for antipsychotic compounds
and withdrawal or discontinuation: “([terms for specific
antipsychotic compounds separated by OR] OR antipsychotic*
OR neuroleptic*) AND (discontinu* OR withdraw*)”. We
included terms for all antipsychotic compounds classified in
the The Anatomical Therapeutic Chemical (ATC) classification
system by the WHO Collaborating Centre for Drug Statistics
Methodology (Supplement Section 1 – search entry) (20). A
selective search of references in the included studies and other
reviews was implemented to identify additional records. No
language restrictions were included, and we acquired
translations from a native speaker to test eligibility criteria of
articles written in languages other than English. The literature
search, study screening, and testing of eligibility criteria were
carried out independently by two MDs (LB, SG) with Endnote,
version X8.2 (Clarivate Analytics). We contacted authors of the
included studies in case of missing information provided contact
information could be retrieved.
Eligibility Criteria
Articles were included when they fulfilled the following criteria.
First, occurrence of antipsychotic withdrawal symptoms was
assessed quantitatively. Second, the study was designed as a
controlled or cohort trial. Third, the group under investigation for
withdrawal symptoms received a placebo substitute after
antipsychotic discontinuation. Fourth, the reported observation
period covered at least 7 days after antipsychotic discontinuation
(the observation period refers to the total duration that an individual
was clinically observed for after antipsychotic discontinuation).
All types of discontinuation (e.g., abrupt or stepwise) and all
study populations (e.g., individuals with psychiatric or non-
psychiatric i l lnesses) were included. Regarding the
antipsychotic treatment before discontinuation, the inclusion
of studies was not restricted to a specific duration of
antipsychotic treatment. Studies were excluded if there was no
information on the exact number of individuals with withdrawal
symptoms. Studies were excluded if they did not report daily
clinical assessments of the individual (i.e., clinical assessment
interval) because short lasting withdrawal symptoms previously
reported in antipsychotics (4) and other psychopharmacological
compounds such as antidepressants (12) otherwise may be
missed. Studies with assessments of only single symptoms such
as a sleep disorder were excluded.
Study Selection, Data Collection,
and Data Extraction
Study selection and classification and coding of data into an
predefined Excel spreadsheet (Microsoft Excel for Mac, versionSeptember 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal Symptoms16.12, Microsoft Corporation) following the recommendations
by the Cochrane Collaboration handbook (17) was carried out
independently by two MDs (LB, SG). Discrepancies were
resolved by consensus with additional review authors (JH, MM).
Risk of Bias
We assessed the risk of bias according to the Cochrane
Collaboration’s tool (21): Studies were assessed as holding a
“low”, “unclear”, or “high” risk of bias in the six domains of
selection bias, performance bias, detection bias, attrition bias,
reporting bias, and other bias. Risk of bias was assessed
independently by two MDs (LB, SG). Discrepancies were
resolved by consensus with additional review authors (JH, MM).
Data Synthesis
The primary outcome measure was withdrawal symptoms after
antipsychotic discontinuation. A random effects meta-analysis of
proportions (17) was carried out for the primary outcome of the
main quantitative analysis and showed the weighted mean of the
proportion of individuals with withdrawal symptoms after
antipsychotic discontinuation and placebo substitution
accompanied by its 95% CI. In the sensitivity analysis, only
studies with an allocation of individuals to a target group that
received a placebo substitute after antipsychotic discontinuation
or a control group that continued antipsychotic treatment were
included. The outcome of the sensitivity analysis was the pooled
odds ratio (OR) for individuals who discontinued the
antipsychotic treatment compared with individuals who
continued the antipsychotic treatment. Number needed to
harm (NNH) was calculated for individuals who discontinued
the antipsychotic treatment compared with individuals who
continued the antipsychotic treatment. Heterogeneity among
studies was assessed with I2 statistics. We intended to assess
publication bias by funnel plots and Egger’s test as recommended
by Sterne et al (22). All statistical analyses were performed with
Stata, version 13.1 (StataCorp LLC). A 2-sided P <0.05 was
considered statistically significant. Analyses were not corrected
for multiple testing.RESULTS
After removal of duplicates, 18,043 studies were retrieved
through the literature search and screened (Supplement
Figure 1). 7 of these screened studies were retrieved through
manual searches. Studies were screened and 119 full-text
manuscripts were assessed for eligibility. We excluded a total
of 114 studies because of the following reasons: withdrawal
symptoms were not assessed in 85 studies, 11 studies were case
reports, no placebo substitute was implemented in nine studies,
only single symptoms such as sleep disorders were assessed in
five studies, the clinical assessment interval was not daily in two
studies, the observation period was less than 7 days in one study,
and no exact number of individuals was reported in one study.
Five articles, published between 1959 and 1976, met the inclusion
criteria for the quantitative analysis (Table 1).Frontiers in Psychiatry | www.frontiersin.org 3Three out of the five eligible studies (studies by Degkwitz et al.
(25), Lacoursiere et al. (8), and Melnyk et al. (26); Table 1) in the
quantitative analysis had implemented a double-blinded design,
setting the participants to placebo (i.e., target group) or to
continuation of antipsychotic treatment (i.e., control group).
The other two out of the five eligible studies in the quantitative
analysis (i.e., studies by Battegay (23)). and Brooks (24); Table 1)
were cohort studies setting the participants to placebo (i.e., target
group) and no control group that continued the antipsychotic.
Individuals in the target group of all included studies had
discontinued antipsychotics abruptly. No individuals in the
included studies discontinued antipsychotics stepwise (also
known as tapered discontinuation). Study populations
primarily focused on individuals with schizophrenia but
diagnostic procedures (e.g., ICD or DSM) were not specified
(Table 1). Individuals were assessed clinically daily in all studies.
Lacoursiere et al. did not report the daily assessments in the
publication but confirmed it through email correspondence with
the authors on January 2, 2019. The observation periods showed
a high variability from 7 days to 7 months. The discontinued
antipsychotic medication comprised different oral dopamine
(D2) receptor antagonists (i.e., also known as “first-generation
neuroleptics/antipsychotics”) in monotherapy or combination
therapy. In the study by Battegay, individuals also stopped other
co-medication (“antidepressants” in 6% of individuals and
diazepam in 4% of individuals). Battegay, Brooks, and
Lacoursiere et al. included cohorts that also discontinued
medication intended to relief “extrapyramidal” or “parkinson”
symptoms (i.e., biperidene, ethybenzatropin, benztropine
methanesulfonate, trihexiphenidyl, or procyclidine hydrochloride).
Lacoursiere et al. reported separate results for cohorts with
additional “antiparkinson agents”. Cohorts with discontinued
other medication than antipsychotics were not included in the
sensitivity analysis. None of the included studies reported a specific
standardized clinical assessment procedure for withdrawal
symptoms. Brooks focused on withdrawal symptoms that were of
at least moderate degree, i.e., “marked and distressing”, which he
detected in 17 individuals. Brooks did not include nine other
individuals with “mild reactions”. These “mild reactions” were not
specified and also excluded from our analysis. All studies showed a
“high” risk of bias according to Cochrane Collaboration’s tool for
assessing risk of bias (Table 1) (21).
Reported symptoms included nausea and vomiting,
abdominal pain, diarrhea, headache, tachycardia, vertigo,
increased perspiration, dry mucous membranes, myalgia,
restlessness, anxiety, tension, insomnia, and hyperkinesia
(Table 2). In addition, Lacoursiere et al. described “isolated
reports of numbness, nightmares, rhinorrhea, and bad taste”.
Battegay (23) reported a significantly higher rates of withdrawal
symptoms in women and the age group above 50 years after
discontinuation of different antipsychotics (23).
Main Analysis
The main quantitative analysis included five studies with a total of
261 individuals (Figure 1). A weighted mean of 0.53 (95% CI, 0.37–
0.70) of individuals showed withdrawal symptoms after abrupt
discontinuation of oral antipsychotic treatment and placeboSeptember 2020 | Volume 11 | Article 569912
TABLE 1 | Included studies on the occurrence of withdrawal symptoms after abrupt antipsychotic discontinuation.
dication discontinued Observation
period after
antipsychotic
discontinuation
Risk of bias according
to Cochrane Collabora-
tion’s tool for assessing
risk of bias
Individuals
with with-
drawal symp-
toms in % (N)
agents” biperidene or
in in all individuals of this
nts” in 6% and diazepam in
iduals of the studyF
7 days High Target group:
86% (12/14)
nts” in 6% and diazepam in
iduals in the studyF
7 days High Target group:
59% (24/41)
l, procyclidine
, or benztropine
ate in “most” individuals
elief extrapyramidal
10 days High Target group:
61% (17/28)A
5-7 months High Target group:
36% (19/53)B
Control group:
11% (4/35)B
esylate as “antiparkinson
dividuals
4 weeks High Target group
25% (4/16)
4 weeks High Target group
38% (10/26)
Control group:
12.5% (1/8)
6 weeks High Target group:
75% (15/20)
Control group:
10% (2/20)
on (to a target group, which discontinued antipsychotic treatment, or a control group, which continued
l was double-blinded and both participating individuals and investigators blinded. ABrooks focused on
did not include 9 other individuals with “mild reactions” also excluded from our analysis. BNew vegetative
, undifferentiated, catatonic, or hebephrenic schizophrenia” and one individual with “acute schizophrenic
entire study (n = 81) including a subgroup without placebo substitution (n = 26/81), which was excluded
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(publication year)
Diagnosis Study design Age and sex Discontinued antipsy-
chotic medication (dose
per day, if specified)
Other m
Battegay (1966) (23) Schizophrenia,
“oligophrenia”,
or “organic brain
damage”
Control: No
Rand.: N. a.
Placebo: Yes
Blinded: No
44% <50
years and
56% >50
years, 57%
femalesF
Derivates of phenotiazine,
thiaxanthene,
butyrophenone, or
piperazinylF
“antiparkinso
ethybenzatro
subgroup
“antidepressa
4% of all indi
“antidepressa
4% of all indi
Brooks (1959) (24) SchizophreniaE Control: No
Rand.: N. a.
Placebo: Yes
Blinded: No
19–53 years,
100% females
Chlorpromazine (150–
600mg) and/or reserpine
(1.5–4mg)
trihexiphenidy
hydrochloride
methanesulfo
intended to “
symptoms”
Degkwitz et al. (1970)
(25)
SchizophreniaE Control: Yes
Rand.: N. s.
Placebo: YesC
Blinded: YesC
20–79 years,
62.5% females
Antipsychotic medication not
specified (mean 388
chlorpromazine units per day
in the target group)
None
Lacoursiere et al.
(1976) (8)
SchizophreniaE Control: Yes
Rand.: N. s.
Placebo: Yes
Blinded: Yes
Mean 37
years, 29%
females
Chlorpromazine and/or other
unspecified antipsychotics
(mean 800 chlorpromazine
units per day)
Benztropine m
agent” in all in
None
Melnyk et al. (1966)
(26)
SchizophreniaD Control: Yes
Rand.: Yes
Placebo: Yes
Blinded: Yes
Age n. s.,
50% females
(target: 65%
females;
control: 35%
females)
Thioridazine or
chlorpromazine (100-600mg)
None
N. s., Not specified; N. a., Not applicable; Control, Control group, which continued antipsychotic treatment; Rand., randomized allocat
antipsychotic treatment); Placebo, the target group received a placebo substitute after antipsychotic discontinuation; Blinded, the tria
withdrawal symptoms that were of at least moderate degree, i.e., “marked and distressing”, which he detected in 17 individuals. Brooks
symptoms and hyperkinesia. CPlacebos biased by not completely identical taste in the study by Degkwitz et al. DIndividuals with “paranoi
reaction”. E“Chronic schizophrenia”. FBattegay reported age and sex distribution, antipsychotic medication, and other medication for the
from this meta-analysis.e
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Brandt et al. Antipsychotic Withdrawal Symptomssubstitution. Heterogeneity among the included trials was high (I2 =
82.98%, P < 0.01; Figure 1). Numbers of included studies were too
low (n = 5) to adequately assess publication bias by funnel plot
inspection or more advanced regression-based assessments.
Sensitivity Analyses
The sensitivity analysis was limited to three studies with a target
and a control group and total of 162 individuals (Figure 2). A
weighted mean of 0.49 (95% CI, 0.26–0.73) of individuals
showed withdrawal symptoms after abrupt discontinuation of
oral antipsychotic treatment and placebo substitution in the
target group. In comparison, the control group only showed a
weighted mean of 0.11 (95% CI, 0.03–0.19) after continuation of
oral antipsychotic treatment.
Heterogeneity among the included trials was high in the
target group (I2 = 83.29%, P < 0.01) and low in the control
group (I2 < 0.01%, P = 0.98).
Odds ratio resulted in 7.97 (95% CI, 2.39–26.58; I2 = 82.7%,
P = 0.003) and number needed to harm (NNH) was 3 when
analyses were restricted to the three studies with allocation to a
target group that received a placebo substitute after abrupt
antipsychotic discontinuation and a control group that
continued antipsychotic treatment (Figure 3).DISCUSSION
To our knowledge, this is the first systematic review and meta-
analysis on the occurrence of withdrawal symptoms afterFrontiers in Psychiatry | www.frontiersin.org 5antipsychotic discontinuation. A weighted average of 53%
individuals showed withdrawal symptoms after abrupt
antipsychotic discontinuation and placebo substitution in this
meta-analysis.
The studies in the main quantitative analysis were characterized
by high risk of bias due to methodological heterogeneity,
discontinuation of different antipsychotic and non-antipsychotic
compounds, and considerable missing information. The
proportion of individuals with withdrawal symptoms in the
target groups showed a high variability, presumably because of
the heterogeneity of study designs and in particular the use of
different antipsychotics as monotherapy or as combination
therapy. The studies by Battegay (23) and Brooks (24) included
no placebo arm with continued antipsychotic treatment and were
excluded in the sensitivity analysis. All cohorts with
discontinuation of other medication than antipsychotics were
also excluded from the sensitivity analysis. The sensitivity
analyses supported the results of the main analysis and showed a
weighted average of 49% in the target group versus 11% in the
control group, an odds ratio of 7.97, and NNH of 3. In this
sensitivity analysis, the proportion of individuals with symptoms in
the control group (continued intake of antipsychotics) showed a
comparatively low variability of 10–12% across studies. The effect
sizes should still be considered as guiding estimates and not exact
values due to high risk of bias.
Withdrawal symptoms after abrupt antipsychotic
discontinuation in the included studies were heterogenous and
affected multiple organ systems (Table 2). Symptoms can be very
related (e.g., agitation and insomnia) or unlike (e.g., vomiting) to
the beginning of a psychotic relapse. In addition, Degkwitz et al.
reported that all individuals with vegetative withdrawal symptoms
and/or hyperkinesia also worsened in psychopathological scores
(25). These findings demonstrate that attributing a particular
symptom to either withdrawal or the beginning of a psychotic
relapse can be a complex task (4, 5, 27) and emphasizes the need
for further psychopathological assessment and a close monitoring
of the development of the symptoms.
The studies in our review (8, 23–26) reported that most
withdrawal symptoms started within 4 weeks after abrupt
antipsychotic discontinuation and subsided after up to 4 weeks
even though certain symptoms such as hyperkinesia may last for
months (23).
A randomized controlled trial (RCT) by Tollefson et al. from
1999 seemed to be in contrast to the findings from this meta-
analysis (28): they did not detect increased rates of symptoms
such as nausea, vomiting, diarrhea, or headache in the group that
received placebo after discontinuation of clozapine 300 mg per
day. The contrast between the RCT and the included studies in
this meta-analysis may be due to the fact that placebo was
administered for three to five days and potential withdrawal
symptoms could only be observed in this shorter period of time.
Withdrawal symptoms with a later onset were not investigated in
the study by Tollefson et al. In comparison, Shiovitz et al.
assessed individuals for seven days after discontinuation of
clozapine 200 mg per day without placebo substitution and
detected withdrawal symptoms in 61% of the 28 individuals (29).TABLE 2 | Clinical features of abrupt oral antipsychotic withdrawal.
Symptoms Nausea and vomiting (8, 24, 26)
Abdominal pain (26)
Diarrhea (25)
Headache (8, 23, 26)
Tachycardia (23, 25)
Vertigo (8, 23)
Increased perspiration (23, 25, 26)
Dry mucous membranes (25)
Myalgia (8, 26)
Restlessness (8, 24–26)
Anxiety (24)
Tension (24)
Insomnia (8, 23–25)
Hyperkinesia (23, 25)
Time of onset Within 4 weeks after discontinuation
(8, 23–26)
Duration 1–4 weeks (hyperkinesia may last months)
(8, 23–26)
Proportion of individuals with
withdrawal symptoms
0.53 (95% CI, 0.37–0.70)A (8, 23–26)
Odds ratio (OR) 7.97 (95% CI, 2.39–26.58; I2 = 82.7%,
P = 0.003)B, (8, 25–26)
Number needed to harm (NNH) 3B (8, 25–26)ABased on main analysis of five trials that abruptly substituted oral antipsychotics with
placebo (Figure 1), the sensitivity analysis showed similar results and a weighted mean of
0.49 (95% CI, 0.26–0.73; Figure 2). Banalysis was restricted to the three studies in the
sensitivity analysis with an allocation to a target group that received a placebo substitute
after abrupt antipsychotic discontinuation or a control group that continued antipsychotic
treatment with a double-blinded design (Figure 3).September 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal SymptomsOnly few data regarding risk factors for the occurrence of
withdrawal symptoms have been reported (4). Battegay observed
that the occurrence of withdrawal symptoms after discontinuation
of different antipsychotics was significantly higher in women and
the age group above 50 years (23). Degkwitz et al. also reported a
higher rate of withdrawal symptoms in women (30) and Azermai
et al. detected a high rate of individuals with withdrawal
symptoms (72%) in a geriatric population (31). These findings
raise the question, if the female and geriatric population areFrontiers in Psychiatry | www.frontiersin.org 6particularly vulnerable for the development of withdrawal
symptoms after antipsychotic discontinuation. No significant
effect of dosage on the type and severity of withdrawal symptoms
was reported in two other studies (last medication: reserpine 1.5–4
mg per day and/or chlorpromazine 150–600 mg per day) (8, 24).
However, it is not known whether dose effects would be detected if
lower dosages would be included in the analyses (8).
Several smaller (n ≤ 30 participants per study) studies
reported specific aspects of sleep disorders after antipsychoticFIGURE 1 | The square data markers indicate the proportion of individuals with withdrawal symptoms in each study, with sizes reflecting the study’s statistical
weight using random-effects meta-analysis of proportions. The horizontal lines indicate 95% CIs. The blue diamond data marker represents the overall proportion
and 95% CI. The vertical dashed line shows the summary effect estimate.FIGURE 2 | The square data markers indicate the proportion of individuals with withdrawal symptoms in each study, with sizes reflecting the statistical weight of the
study using random-effects meta-analysis of proportions. The horizontal lines indicate 95% CIs. The blue diamond data marker represents the subtotal and overall
proportion and 95% CI. The vertical dashed line shows the overall effect estimate for both target and control together.September 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal Symptomswithdrawal such as mean decreased REM sleep (32–34), reduced
total sleep duration (34), decreased sleep efficiency (35), or
decreased sleep continuity (33). In these studies, the sleep
disorders were detected during the first days to weeks following
withdrawal from first generation antipsychotics (e.g., haloperidol or
mesoridazine) or second generation antipsychotics (e.g., risperidone
or olanzapine) (32–35).
Abrupt withdrawal of haloperidol was associated with a
significant increase in dyskinesia beginning in the second week
post-withdrawal in a study with fifteen participants with
schizophrenia (36). A case series (37) and case report (38)
indicated occurrence of dyskinesia and dystonia after abrupt
withdrawal of clozapine. In another study with 34 children, 6 to
12 years of age and diagnosed with schizophrenia, 41% of the
children showed involuntary movements and ataxia after
withdrawal of different antipsychotics (i.e., fluphenazine,
haloperidol, thioridazine, trifluoperazine, and thiothixene) (39).
In half of the children with involuntary movements and ataxia,
symptoms did not disappear spontaneously within 2 to 5 weeks
after withdrawal but only after antipsychotic treatment was
started again (39).
The included studies in this systematic review and meta-
analysis did not implement stepwise discontinuation but
Greenberg and Roth compared abrupt discontinuation (n = 21
persons) with a stepwise and slow discontinuation over the
duration of 336 days (n = 21 persons) of chlorpromazine
(initial average dose of 510 mg per day) (40). They reported
that the “majority” of individuals after abrupt discontinuation
suffered from withdrawal symptoms compared to none of the
individuals after stepwise reduction. A recent study by Emsley
et al. from 2018 showed no significant difference in blood
pressure and heart rate in individuals after discontinuation of
long acting paliperidone palmitate once monthly injections
compared to individuals with continued treatment (41). Based
on these limited findings, it could be hypothesized that the long
acting kinetic properties with a very slow decrease ofFrontiers in Psychiatry | www.frontiersin.org 7antipsychotic dosage over weeks may reduce the occurrence of
withdrawal symptoms similar to the stepwise reduction in the
study by Greenberg and Roth. In a meta-analysis by Leucht et al.
(42), the authors reported that the increased occurrence of
dyskinesia was probably related to abrupt antipsychotic
withdrawal, but assessment of the disorder by appropriate
criteria was lacking (42). Furthermore, specific tapering
strategies to reduce the risk of withdrawal symptoms were
recently recommended for antidepressants: For example,
Horowitz and Taylor (43) proposed a slow and hyperbolical
taper strategy to mitigate SSRI withdrawal symptoms (43).
It has been suggested that even dose reductions without
complete discontinuation of antipsychotics may cause withdrawal
symptoms (5). More research is needed to investigate the risk of
withdrawal symptoms prior to complete discontinuation such as
during different tapering procedures or during dose reductions
without complete discontinuation.
The findings from this meta-analysis indicate that withdrawal
symptoms after abrupt antipsychotic discontinuation occur
frequently. This finding is of importance when planning a safe
therapy and implicates that the risk of withdrawal symptoms after
antipsychotic discontinuation requires consideration in clinical
practice and health policy. Future research may also assess the
effect antipsychotic withdrawal symptoms on other parameters such
as psychosocial functioning and quality of life. Current
schizophrenia guidelines (e.g., by the National Institute for Health
and Clinical Excellence in the United Kingdom (10) or German
Association for Psychiatry, Psychotherapy and Psychosomatics (9))
provide information on how to prepare and approach
discontinuation of antipsychotics (e.g., tapering strategies).
This finding also has implications for the design and
interpretation of clinical trials with antipsychotics. For
example, a washout phase at the beginning of a clinical trial
could possibly lead to an increase of adverse events unrelated to
the trial medication or placebo if the duration of the washout
phase is shorter than the duration of withdrawal symptoms fromFIGURE 3 | The square data markers indicate the proportion of individuals with withdrawal symptoms in each study, with sizes reflecting the statistical weight of the
study using random-effects meta-analysis. The horizontal lines indicate 95% CIs. The blue diamond data marker represents the overall proportion and 95% CI. The
vertical dashed line shows the overall effect estimate, and the continuous line represents the line of no effect (OR = 1).September 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal Symptomsthe individual prestudy antipsychotics. Little is known about the
effect of withdrawal symptoms on the occurrence of adverse
events in clinical trials with antipsychotics and more research is
needed to elucidate this potentially critical effect.
Future research may address effects of antipsychotic
withdrawal in different psychiatric diagnoses and take into
account whether effects are dependent on dose or duration of
antipsychotic treatment and pharmacological characteristics
such as elimination half-life or anticholinergic properties.
Limitations
This systematic review and meta-analysis confirmed the initial
assumption that withdrawal symptoms occur frequently after
abrupt antipsychotic discontinuation. The representativeness
and validity of our findings are, however, limited by the
following aspects:
The included studies are few, with small number of subjects,
not recent, methodologically heterogenous, and characterized by a
high risk of bias. So-called second-generation antipsychotics,
which are considered first-line treatment and differ in their
receptor profiles, were not included. The lack of recent
discontinuation studies may be related to ethical considerations,
as discontinuation of antipsychotics increases the risk of relapse.
Therefore, the existing data are largely from studies published
before 1980. Moreover, it remains elusive whether individuals
following the first exposure to an antipsychotic are at different risk
to develop withdrawal symptoms than patients following a chronic
exposure to an antipsychotic. Large high quality randomized
controlled trials with a focus on discontinuation with
antipsychotics are needed. The proportion of individuals with
withdrawal symptoms may further differ according to
characteristics of individuals such as age, sex, and specific types
of antipsychotic drugs (23). Drawing conclusions from this meta-
analysis should consider these limitations and results may thus be
used as guiding values only.CONCLUSION
In this systematic review and meta-analysis of five studies, the
proportion of individuals with withdrawal symptoms after abrupt
oral antipsychotic discontinuation was increased. In studies with a
control group that continued antipsychotic treatment, only aFrontiers in Psychiatry | www.frontiersin.org 8proportion of 0.11 of individuals in the control group showed
withdrawal symptoms compared to a proportion of 0.49 of
individuals after abrupt antipsychotic discontinuation (odds
ratio 7.97 and NNH 3); available information was limited to
studies with so-called first-generation antipsychotics and a high
risk of bias. These findings suggest that withdrawal symptoms
may occur frequently after abrupt discontinuation of oral
antipsychotics but the lack of randomized controlled trials with
low risk of bias highlights the need for further research.DATA AVAILABILITY STATEMENT
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Charité – Universitätsmedizin Berlin.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at:
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.569912/
full#supplementary-material
SUPPLEMENTARY FIGURE 1 | PRISMA flowchart.
SUPPLEMENTARY DATA SHEET 1 | Database search entry.REFERENCES
1. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World
Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological
Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of
schizophrenia and management of antipsychotic-induced side effects.World J Biol
Psychiatry (2013) 14:2–44. doi: 10.3109/15622975.2012.739708
2. Correll CU. From receptor pharmacology to improved outcomes:
individualising the selection, dosing, and switching of antipsychotics. Eur
Psychiatry (2010) 25:12–21. doi: 10.1016/S0924-9338(10)71701-6
3. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter
N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the
acute treatment of adults with multi-episode schizophrenia: a systematicreview and network meta-analysis. Lancet (2019) 394:939–51. doi: 10.1016/
S0140-6736(19)31135-3
4. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, et al.
Withdrawal Symptoms and Rebound Syndromes Associated with Switching
and Discontinuing Atypical Antipsychotics: Theoretical Background and
Practical Recommendations. CNS Drugs (2013) 27:545–72. doi: 10.1007/
s40263-013-0079-5
5. ChouinardG, SamahaA-N,ChouinardV-A, PerettiC-S,KanaharaN,TakaseM,
et al. Antipsychotic-Induced Dopamine Supersensitivity Psychosis:
Pharmacology, Criteria, and Therapy. Psychother Psychosom (2017) 86:189–
219. doi: 10.1159/000477313
6. Lader M. Benzodiazepine withdrawal states. In: Trimble MR,
editor. Benzodiazepines divided. New York Chichester: Wiley and Sons, (1983).September 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal Symptoms7. Li M. Antipsychotic-induced sensitization and tolerance: Behavioral
characteristics, developmental impacts, and neurobiological mechanisms.
J Psychopharmacol (2016) 30:749–70. doi: 10.1177/0269881116654697
8. Lacoursiere RB, Spohn HE, Thompson K. Medical effects of abrupt
neuroleptic withdrawal. Compr Psychiatry (1976) 17:285–94. doi: 10.1016/
0010-440X(76)90002-X
9. DGPPN e.V. (Hrsg.) für die Leitliniengruppe: S3-Leitlinie Schizophrenie.
Kurzfassung, 2019, Version 1.0, updated on 15. March 2019, Available at:
https://www.awmf.org/leitlinien/detail/ll/038-009.html
10. National Collaborating Centre for Mental Health (UK). Psychosis and
Schizophrenia in Adults: Treatment and Management. (London: National
Institute for Health and Care Excellence (UK)); 2014. https://www.nice.org.
ukguidancecgresourcespsychosis-andschizophrenia-in-adults-prevention-and-
management-pdf-.
11. Heinz A, Daedelow LS, Wackerhagen C, Di Chiara G. Addiction theory
matters-Why there is no dependence on caffeine or antidepressant
medication. Addict Biol (2020) 25:e12735. doi: 10.1111/adb.12735
12. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and
Rebound Phenomena. Dtsch Arztebl Int (2019) 116:355–61. doi: 10.3238/
arztebl.2019.0355
13. Hollister LE, Eikenberry DT, Raffel S. Chlorpromazine in nonpsychotic
patients with pulmonary tuberculosis. Am Rev Respir Dis (1960) 81:562–6.
doi: 10.1164/arrd.1960.81.4.562
14. Reidenberg MM. Drug Discontinuation Effects Are Part of the Pharmacology
of a Drug. J Pharmacol Exp Ther (2011) 339:324–8. doi: 10.1124/
jpet.111.183285
15. Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of
transdermal clonidine therapy. Am J Med (1987) 82:17–9. doi: 10.1016/0002-
9343(87)90371-8
16. Dilling H, Freyberger HJ. Taschenführer zur ICD-10-Klassifikation psychischer
Störungen. Hogrefe, vorm. Verlag Hans Huber: Göttingen, Germany (2013).
17. Deeks JJ, Higgins J, Altman DG, Green S. Part1: Cochrane reviews. Part 2:
general methods for Cochrane reviews. In: Higgins JPT, Green S, eds. Cochrane
Handbook for Systematic Reviews of Interventions. Version 5.1.0. The
Cochrane Collaboration (2011). https://handbook-5-1.cochrane.org/
18. Moher D, Liberati A, Tetzlaff J, Altmann D G. PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. Ann Intern Med (2009) 151(4):264–W64. doi: 10.7326/0003-
4819-151-4-200908180-00135
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting. Meta-
analysis Of Observational Studies in Epidemiology (MOOSE) group. in. JAMA
(2000) 283:2008–12. doi: 10.1001/jama.283.15.2008
20. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical
Therapeutic Chemical (ATC) classification system. Norwegian Institute of
Public Health. Available at: https://www.whocc.no.
21. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al.
Cochrane Bias Methods GroupCochrane Statistical Methods Group. The
Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
BMJ (2011) 343:d5928–8. doi: 10.1136/bmj.d5928
22. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al.
Recommendations for examining and interpreting funnel plot asymmetry in
meta-analyses of randomised controlled trials. BMJ (2011) 343:d4002–2. doi:
10.1136/bmj.d4002
23. Battegay R. Drug dependence as a criterion for differentiation of psychotropic
drugs. Compr Psychiatry (1966) 7:501–9. doi: 10.1016/S0010-440X(66)80030-5
24. Brooks GW. Withdrawal From Neuroleptic Drugs. Am J Psychiatry (1959)
115:931–2. doi: 10.1176/ajp.115.10.931
25. Degkwitz R, Bauer MP, Gruber M, Hampel G, Luxenburger O, Richartz M,
et al. Der zeitliche Zusammenhang zwischen dem Auftreten persistierender
extra-pyramidaler Hyperkinesen und Psychoserecidiven nach abrupter
Unterbrechung langfristiger neuroleptischer Behandlung chronisch
schizophrener Kranken. [Time relationship between the appearance of
persisting extrapyramidal hyperkineses and psychotic recurrences following
sudden interruption of prolonged neuroleptic therapy of chronic
schizophrenic patients]. Arzneimittelforschung (1970) 20:890–3.
26. Melnyk WT, Worthington AG, Laverty MB. Abrupt withdrawal of
chlorpromazine and thioridazine from schizophrenic in-patients.Frontiers in Psychiatry | www.frontiersin.org 9Can Psychiatr Assoc J (1966) 11:410–3. doi: 10.1177/07067437
6601100507
27. Leucht S, Davis JM. Do antipsychotic drugs lose their efficacy for relapse
prevention over time? Br J Psychiatry (2017) 211:127–9. doi: 10.1192/
bjp.bp.117.201103
28. Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ.
Controlled, double-blind investigation of the clozapine discontinuation
symptoms with conversion to either olanzapine or placebo. The
Collaborative Crossover Study Group. J Clin Psychopharmacol (1999)
19:435–43. doi: 10.1097/00004714-199910000-00007
29. Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, et al.
Cholinergic rebound and rapid onset psychosis following abrupt
clozapine withdrawal. Schizophr Bull (1996) 22:591–5. doi: 10.1093/
schbul/22.4.591
30. Degkwitz R, Binsack KF, Herkert H, Luxenburger O, Wenzel W. Zum
Problem der persistierenden extrapyramidalen Hyperkinesien nach
langfristiger Anwendung von Neuroleptika [On the problem of persistent
extrapyramidal hyperkinesia following prolonged use of neuroleptics].
Nervenarzt (1967) 4:170–4.
31. Azermai M, Petrovic M, Engelborghs S, Elseviers MM, Van der Mussele S,
Debruyne H, et al. The effects of abrupt antipsychotic discontinuation in
cognitively impaired older persons: A pilot study. Aging Ment Health (2013)
17:125–32. doi: 10.1080/13607863.2012.717255
32. Adam K, Allen S, Carruthers-Jones I, Oswald I, Spence M. Mesoridazine and
human sleep. Br J Clin Pharmacol (1976) 3:157–63. doi: 10.1111/j.1365-
2125.1976.tb00583.x
33. Nofzinger EA, van Kammen DP, Gilbertson MW, Gurklis JA, Peters JL.
Electroencephalographic sleep in clinically stable schizophrenic patients: two-
weeks versus six-weeks neuroleptic-free. BPS (1993) 33:829–35. doi: 10.1016/
0006-3223(93)90024-8
34. Thaker GK, Wagman AM, Kirkpatrick B, Tamminga CA. Alterations in sleep
polygraphy after neuroleptic withdrawal: a putative supersensitive
dopaminergic mechanism. BPS (1989) 25:75–86. doi: 10.1016/0006-3223
(89)90149-2
35. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic
withdrawal on behavior and sleep/wake activity in nursing home residents
with dementia: a randomized, placebo-controlled, double-blinded study. The
Bergen District Nursing Home Study. J Am Geriatr Soc (2004) 52:1737–43.
doi: 10.1111/j.1532-5415.2004.52470.x
36. Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in
psychopathology and dyskinesia after neuroleptic withdrawal in a double-
blind design. Schizophr Res (1993) 10:267–71. doi: 10.1016/0920-9964(93)
90061-M
37. Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR.
Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin
Psychiatry (1998) 59:472–7. doi: 10.4088/JCP.v59n0906
38. Sarma S, Chetia D, Raha B, Agarwal G. Clozapine withdrawal emergent
dystonia, oculogyric crisis and rebound psychosis in a single patient. Ther Adv
Psychopharmacol (2016) 6:145–6. doi: 10.1177/2045125315591928
39. Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences
of psychotropic drug withdrawal in schizophrenic children. J Autism Child
Schizophr (1973) 3:247–53. doi: 10.1007/BF01538282
40. Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal
of chlorpromazine in hospitalized chronic schizophrenic patients. Am J
Psychiatry (1966) 123:221–6. doi: 10.1176/ajp.123.2.221
41. Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW. Relapse After
Antipsychotic Discontinuation in Schizophrenia as a Withdrawal
Phenomenon vs Illness Recurrence. J Clin Psychiatry (2018) 79:1–9. doi:
10.4088/JCP.17m11874
42. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al.
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia:
a systematic review and meta-analysis. Lancet (2012) 379:2063–71. doi:
10.1016/S0140-6736(12)60239-6
43. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal
symptoms. Lancet Psychiatry (2019) 6:538–46. doi: 10.1016/S2215-0366(19)30032-X
Conflict of Interest: AHa is Editor of the World Federation of Societies of
Biological Psychiatry (WFSBP) guideline schizophrenia and co-editor of theSeptember 2020 | Volume 11 | Article 569912
Brandt et al. Antipsychotic Withdrawal SymptomsGerman S3-guideline schizophrenia. He was member of an advisory board of
Janssen, Lundbeck, and Otsuka and received payed speakership for scientific talks
from these companies.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.Frontiers in Psychiatry | www.frontiersin.org 10Copyright © 2020 Brandt, Bschor, Henssler, Müller, Hasan, Heinz and Gutwinski.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) and the copyright owner(s) are credited and
that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.September 2020 | Volume 11 | Article 569912
